Login to Your Account



Hyaluronidase Failure Trips Partners; Halozyme Plummets

By Marie Powers
Staff Writer

Friday, August 3, 2012
Halozyme Therapeutics Inc. took a double hit Thursday as FDA concerns about its recombinant human hyaluronidase (rHuPH20) enzyme sidetracked programs at two partners and sent the stock into a tailspin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription